During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the […]

The world of analytical microchips is the fastest growing technology segment in the life sciences today. The range of applications to which these miniature laboratories may be directed is very broad–covering fields as different as pharmaceutical development, food testing, clinical diagnostics, forensics, and environmental analysis. Moreover, while the number of such products is currently limited, […]

To succeed in the diagnostics market of the 21st Century, a company has to have either a strong niche position in a particular market segment or be a jack of all trades. In either case, a full or comprehensive menu is critical. Why reinvent the wheel? Most tests and systems are already available somewhere, offered […]

In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of […]

Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the […]

Since our last edition of this report in 2007, the oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the […]